Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), announced the appointment of Estelle Grasset, PhD in Biology and Biotechnology, as Project Manager – Research & Development.
Physiogenex appoints Dr. Estelle Grasset as Project Manager
Estelle will bring her strong expertise in GLP-1 signalling, neuronal gut-brain axis, gut microbiota, and animal models of type 2 diabetes to optimize customers’ drugs preclinical development. On the research side, she will develop new animal models of metabolic comorbidities, as well as in vivo and in vitro models to study GLP-1 signalling, neuronal gut-brain axis and gut microbiota..
Physiogenex is a leading preclinical research organization providing non-clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.